PE20140571A1 - USE OF SUBSTITUTE 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINES - Google Patents
USE OF SUBSTITUTE 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINESInfo
- Publication number
- PE20140571A1 PE20140571A1 PE2013002187A PE2013002187A PE20140571A1 PE 20140571 A1 PE20140571 A1 PE 20140571A1 PE 2013002187 A PE2013002187 A PE 2013002187A PE 2013002187 A PE2013002187 A PE 2013002187A PE 20140571 A1 PE20140571 A1 PE 20140571A1
- Authority
- PE
- Peru
- Prior art keywords
- dihydroimidazo
- quinazolin
- alkyl
- quinazolines
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 2,3-DIHIDROIMIDAZO[1,2-c]QUINAZOLINAS DE FORMULA (I) DONDE R1 ES -(CH2)n-(CHR4)-(CH2)m-N(R5)(R5'), EN DONDE R4 ES H, HIDROXI O ALCOXI; R5 Y R5' SON CADA UNO H, ALQUILO, CICLOALQUILALQUILO, ALCOXIALQUILO, ENTRE OTROS; n ES DE 1 A 4; m ES DE 0 A 4; R2 ES HETEROARILO OPCIONALMENTE SUSTITUIDO CON R6, DONDE R6 ES HALOGENO, ALQUILO, ARILO, ENTRE OTROS; R3 ES ALQUILO O CICLOALQUILO. SON COMPUESTOS PREFERIDOS: N-[7-METOXI-8-(3-MORFOLIN-4-ILPROPOXI)-2,3-DIHIDROIMIDAZO[1,2-c]QUINAZOLIN-5-IL]PIRIMIDIN-5-CARBOXAMIDA; N-(8-{3-[(2R,6S)-2,6-DIMETILMORFOLIN-4-IL]PROPOXI}-7-METOXI-2,3-DIHIDROIMIDAZO[1,2-c]QUINAZOLIN-5-IL)NICOTINAMIDA; N-(8-{3-[(2R,6S)-2,6-DIMETILMORFOLIN-4-IL]PROPOXI}-7-METOXI-2,3-DIHIDROIMIDAZO[1,2-c]QUINAZOLIN-5-IL)-2,4-DIMETIL-1,3-TIAZOL-5-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE CANCER DE MAMAREFERS TO COMPOUNDS DERIVED FROM 2,3-DIHYDROIMIDAZO [1,2-c] QUINAZOLINES OF FORMULA (I) WHERE R1 IS - (CH2) n- (CHR4) - (CH2) mN (R5) (R5 '), IN WHERE R4 IS H, HYDROXY OR ALCOXY; R5 AND R5 'ARE EACH H, ALKYL, CYCLOALKYLALKYL, ALCOXYALKYL, AMONG OTHERS; n IS FROM 1 TO 4; m IS 0 TO 4; R2 IS HETEROARYL OPTIONALLY SUBSTITUTED WITH R6, WHERE R6 IS HALOGEN, ALKYL, ARYL, AMONG OTHERS; R3 IS ALKYL OR CYCLOALKYL. PREFERRED COMPOUNDS ARE: N- [7-METHOXY-8- (3-MORPHOLIN-4-ILPROPOXY) -2,3-DIHYDROIMIDAZO [1,2-c] QUINAZOLIN-5-IL] PYRIMIDIN-5-CARBOXAMIDE; N- (8- {3 - [(2R, 6S) -2,6-DIMETHYLMORPHOLIN-4-IL] PROPOXY} -7-METOXY-2,3-DIHYDROIMIDAZO [1,2-c] QUINAZOLIN-5-IL) NICOTINAMIDE; N- (8- {3 - [(2R, 6S) -2,6-DIMETHYLMORPHOLIN-4-IL] PROPOXY} -7-METOXY-2,3-DIHYDROIMIDAZO [1,2-c] QUINAZOLIN-5-IL) -2,4-DIMETHYL-1,3-THIAZOL-5-CARBOXAMIDE; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE USEFUL IN THE TREATMENT OF BREAST CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11161142 | 2011-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140571A1 true PE20140571A1 (en) | 2014-05-19 |
Family
ID=45894478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002187A PE20140571A1 (en) | 2011-04-05 | 2012-03-29 | USE OF SUBSTITUTE 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINES |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10202385B2 (en) |
| EP (1) | EP2694069A1 (en) |
| JP (1) | JP6013446B2 (en) |
| KR (1) | KR102006033B1 (en) |
| CN (1) | CN103608018B (en) |
| AP (1) | AP3751A (en) |
| AR (1) | AR088730A1 (en) |
| AU (2) | AU2012238887A1 (en) |
| BR (1) | BR112013025517A2 (en) |
| CA (1) | CA2832120C (en) |
| CL (1) | CL2013002869A1 (en) |
| CU (1) | CU24349B1 (en) |
| DO (1) | DOP2013000224A (en) |
| EA (1) | EA027670B1 (en) |
| EC (1) | ECSP13013007A (en) |
| GT (1) | GT201300235A (en) |
| IL (1) | IL228435A0 (en) |
| JO (1) | JO3733B1 (en) |
| MA (1) | MA35015B1 (en) |
| MX (1) | MX2013011582A (en) |
| MY (1) | MY169532A (en) |
| PE (1) | PE20140571A1 (en) |
| SG (1) | SG193577A1 (en) |
| TN (1) | TN2013000402A1 (en) |
| TW (1) | TWI639599B (en) |
| UA (1) | UA114177C2 (en) |
| UY (1) | UY33984A (en) |
| WO (1) | WO2012136549A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101897881B1 (en) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | Certain chemical entities, compositions and methods |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| ES2637113T3 (en) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedures for preparing isoquinolinones and solid forms of isoquinolinones |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| JP6368353B2 (en) | 2013-04-08 | 2018-08-01 | バイエル ファーマ アクチエンゲゼルシャフト | Use of substituted 2,3-dihydroimidazo [1,2-c] quinazolines for the treatment of lymphoma |
| WO2015082376A2 (en) * | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Use of pi3k-inhibitors |
| US20150320755A1 (en) * | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| WO2016087490A1 (en) * | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| KR101665234B1 (en) * | 2015-02-10 | 2016-10-12 | 순천향대학교 산학협력단 | Compositions and health functional food for the prevention of bone loss |
| US10406162B2 (en) | 2015-03-09 | 2019-09-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinations |
| CA3016584A1 (en) | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CA3037626A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| US11185549B2 (en) | 2017-06-28 | 2021-11-30 | Bayer Consumer Care Ag | Combination of a PI3K-inhibitor with an androgen receptor antagonist |
| EP3843743A1 (en) * | 2018-08-28 | 2021-07-07 | Bayer AS | Combination of pi3k-inhibitors and targeted thorium conjugates |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1400959A (en) | 1919-04-26 | 1921-12-20 | Ste Chim Usines Rhone | Process and apparatus for carrying out chemical reactions by catalysis |
| US1539891A (en) | 1920-08-09 | 1925-06-02 | Harry A Lewis | Magnetic lifting device |
| US1450048A (en) | 1921-09-24 | 1923-03-27 | Mary S Patterson | Nut lock |
| BE397809A (en) | 1932-08-25 | |||
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| AU2002252160A1 (en) | 2001-03-01 | 2002-09-19 | Northwest Biotherapeutics, Inc. | Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation |
| JP2005532070A (en) | 2002-07-03 | 2005-10-27 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | Method for identifying modulators of MDA-7-mediated apoptosis |
| UA82205C2 (en) | 2002-09-30 | 2008-03-25 | Байер Фармасьютикалз Корпорейшн | Fused azole-pyrimidine derivatives |
| RU2318500C2 (en) * | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Method for on body by target delivery of biologically active substances in mitochondria, pharmaceutical composition for its realization and compound used for this aim |
| JP5190233B2 (en) | 2006-09-01 | 2013-04-24 | パナソニック株式会社 | Wireless communication device |
| AR064106A1 (en) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED QUINAZOLINE USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISEASES ASSOCIATED WITH ANGIOGENESIS |
| US20090098118A1 (en) * | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| WO2009091550A2 (en) * | 2008-01-14 | 2009-07-23 | Bayer Healthcare Llc | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis |
| WO2009126172A1 (en) | 2008-04-11 | 2009-10-15 | The Trustees Of Columbia University In The City Of New York | Resistance to polyphenon e due to increased bcl-2 expression |
| MX339476B (en) | 2008-04-18 | 2016-05-27 | Reata Pharmaceuticals Inc | Compounds including an anti-inflammatory pharmacore and methods of use. |
| US8071315B2 (en) * | 2008-04-30 | 2011-12-06 | Sanford-Burnham Medical Research Institute | Detecting Bcl-B expression in cancer and uses thereof |
| FR2932483A1 (en) * | 2008-06-13 | 2009-12-18 | Cytomics Systems | COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS. |
| US8128386B2 (en) | 2008-06-26 | 2012-03-06 | Hamilton Sundstrand Corporation | Variable flow pumping system |
| EP2168582A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| EP2168583A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| JP5336306B2 (en) | 2008-10-20 | 2013-11-06 | 信越化学工業株式会社 | Resist underlayer film forming method, pattern forming method using the same, and resist underlayer film material |
| SI2992899T1 (en) | 2009-05-14 | 2020-10-30 | Bayer Intellectual Property Gmbh | Enhanced immune response in avian species |
| MA34158B1 (en) * | 2010-04-16 | 2013-04-03 | Bayer Ip Gmbh | COMBINATIONS CONTAINING SUBSTITUTED 2,3-DIHYDROIMIDAZO {1,2-C] QUINAZOLINE |
| UA112517C2 (en) | 2010-07-06 | 2016-09-26 | Новартіс Аг | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES |
| UA113280C2 (en) | 2010-11-11 | 2017-01-10 | AMINOSPIRT-SUBSTITUTED Derivatives of 2,3-Dihydroimimidase $ 1,2-c] QINAZOLINE, SUITABLE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS, DISEASES AND DISEASES | |
| NZ612285A (en) | 2010-12-22 | 2015-09-25 | Bayer Ip Gmbh | Enhanced immune response in bovine species |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| US9539891B2 (en) | 2012-09-21 | 2017-01-10 | Toyota Jidosha Kabushiki Kaisha | Hybrid vehicle driving apparatus |
-
2012
- 2012-03-27 JO JOP/2012/0065A patent/JO3733B1/en active
- 2012-03-28 AR ARP120101035A patent/AR088730A1/en active Pending
- 2012-03-28 UY UY0001033984A patent/UY33984A/en not_active Application Discontinuation
- 2012-03-28 TW TW101110917A patent/TWI639599B/en not_active IP Right Cessation
- 2012-03-29 WO PCT/EP2012/055595 patent/WO2012136549A1/en active Application Filing
- 2012-03-29 SG SG2013071121A patent/SG193577A1/en unknown
- 2012-03-29 EP EP12710955.1A patent/EP2694069A1/en not_active Withdrawn
- 2012-03-29 MX MX2013011582A patent/MX2013011582A/en unknown
- 2012-03-29 PE PE2013002187A patent/PE20140571A1/en not_active Application Discontinuation
- 2012-03-29 UA UAA201312764A patent/UA114177C2/en unknown
- 2012-03-29 CN CN201280027514.5A patent/CN103608018B/en not_active Expired - Fee Related
- 2012-03-29 MA MA36289A patent/MA35015B1/en unknown
- 2012-03-29 EA EA201301106A patent/EA027670B1/en not_active IP Right Cessation
- 2012-03-29 CA CA2832120A patent/CA2832120C/en active Active
- 2012-03-29 US US14/009,751 patent/US10202385B2/en active Active
- 2012-03-29 AU AU2012238887A patent/AU2012238887A1/en not_active Abandoned
- 2012-03-29 JP JP2014503077A patent/JP6013446B2/en not_active Expired - Fee Related
- 2012-03-29 MY MYPI2013701876A patent/MY169532A/en unknown
- 2012-03-29 AP AP2013007147A patent/AP3751A/en active
- 2012-03-29 CU CUP2013000134A patent/CU24349B1/en unknown
- 2012-03-29 BR BR112013025517A patent/BR112013025517A2/en not_active Application Discontinuation
- 2012-03-29 KR KR1020137028953A patent/KR102006033B1/en active IP Right Grant
-
2013
- 2013-09-15 IL IL228435A patent/IL228435A0/en unknown
- 2013-10-03 TN TNP2013000402A patent/TN2013000402A1/en unknown
- 2013-10-04 DO DO2013000224A patent/DOP2013000224A/en unknown
- 2013-10-04 GT GT201300235A patent/GT201300235A/en unknown
- 2013-10-04 CL CL2013002869A patent/CL2013002869A1/en unknown
- 2013-11-04 EC ECSP13013007 patent/ECSP13013007A/en unknown
-
2017
- 2017-05-24 AU AU2017203474A patent/AU2017203474B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140571A1 (en) | USE OF SUBSTITUTE 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINES | |
| PE20140411A1 (en) | DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE SUBSTITUTED WITH AMINOALCOHOLS WHICH ARE USEFUL TO TREAT HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | |
| PE20141205A1 (en) | SPIRO- [1,3] -OXACINS AND SPIRO- [1,4] -OXACEPINS AS INHIBITORS OF BACE1 AND / OR BACE2 | |
| PE20151780A1 (en) | USE OF 2 - 3 DIHYDROIMIDAZO [1,2- C] QUINAZOLINES SUBSTITUTE | |
| PE20142452A1 (en) | CYCLIC AMIDES AS INHIBITORS OF MetAP-2 | |
| PE20171177A1 (en) | JAK INHIBITING AMINOPYRIMIDINYL COMPOUNDS | |
| PE20141973A1 (en) | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | |
| EA201070169A1 (en) | 2,3-DIHYDROBENZO [1,4] DIOXIN-2-ILMETHYL DERIVATIVES AS AN ALPHA2S ANTAGONISTS FOR THE APPLICATION IN THE TREATMENT OF DISEASES OF THE CIRCULAR NERVOUS SYSTEM | |
| PE20190653A1 (en) | NEW DERIVATIVES OF PIRROL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| EA201591027A1 (en) | POLYCYCLIC CARBAMOILPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATIONS | |
| CL2012003604A1 (en) | Heterocyclic compounds derived from substituted pyridine carboxamide; Preparation process; pharmaceutical composition; pharmaceutical combination; use in the treatment of cell proliferative disorders, parkinson's disease, cancer, among others. | |
| EA201300610A1 (en) | HINAZOLINCARBOXAMIDASETIDINE | |
| EA201270808A1 (en) | NEW FORMS OF RIFAXIMINE AND THEIR APPLICATION | |
| EA201200218A1 (en) | NEW BICYCLIC UREA COMPOUNDS | |
| TW201129565A (en) | Tricyclic heterocyclic compounds, compositions and methods of use thereof | |
| PE20151249A1 (en) | PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF JAK KINASES | |
| EA201490647A1 (en) | DERIVATIVES OF BENZOTHIAZOL-6-LUCUS ACID AND THEIR APPLICATION FOR THE TREATMENT OF HIV INFECTION | |
| EA201201343A1 (en) | DERIVATIVES OF 4-AMINOPYRIMIDINE AND THEIR ACTING MATTER AS ANTAGONISTS OF ADENOSIN RECEPTOR A | |
| EA201592082A1 (en) | 3,4-DIHYDRO-ISOHINOLIN-2 (1H) -ILY COMPOUNDS | |
| CL2007001710A1 (en) | Substituted amino-pyrazolopyridine derivatives; Preparation method; pharmaceutical composition; and use in the treatment of diseases such as tumors, rheumatoid arthritis, diseases of deregulated vascular growth, among others. | |
| NZ708909A (en) | Substituted reverse pyrimidine bmi-1 inhibitors | |
| EA201490493A1 (en) | PIRANO [3,2-D] [1,3] TIAZOLE AS GLYOZIDASE INHIBITORS | |
| EA201400338A1 (en) | DERIVATIVES OF AMINOPYRIMIDINE FOR USING AS KINASE ACTIVITY MODULATORS | |
| EA201300186A1 (en) | BICYCLIC AZAGETEROCYCLIC CARBOSAMIDES | |
| RU2013144571A (en) | ALIN-SUBSTITUTED KINAZAZOLES AND WAYS OF THEIR APPLICATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |